Bevacizumab for metastatic colorectal cancer with chromosomal instability: Cost-effectiveness analysis for a novel precision treatment approach in Germany, Ireland and Spain

by on 11 de maig de 2026 with No hi ha comentaris
  • Briody, J., Miller, I. S., O’Mahony, J. F., Tilson, L., O’Farrell, A. C., Chen, Q., Murphy, V., Casey, O., Schulte, N., Ebert, M. P., Prehn, J. H. M., Lambrechts, D., Ylstra, B., Dienstmann, R., Byrne, A. T., & Bennett, K. (2026). Bevacizumab for metastatic colorectal cancer with chromosomal instability: Cost-effectiveness analysis for a novel precision treatment approach in Germany, Ireland and Spain. PharmacoEconomics, 44(3), 359-374. https://doi.org/10.1007/s40273-025-01585-x

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *